ITCI — Intra-Cellular Therapies Share News
0.000.00%
Last trade - 00:00- $14.04bn
- $13.04bn
- $680.85m
Intra-Cellular Therapies up on beating Q3 sales estimates
Intra-Cellular Therapies Inc reports results for the quarter ended in September - Earnings Summary
Brief: Intra-Cellular Therapies Reports Third Quarter Results
Intra-Cellular Therapies Inc expected to post a loss of 81 cents a share - Earnings Preview
Intra-Cellular falls as Goldman Sachs cuts to 'neutral'
Intra-Cellular Therapies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP-Amazon.Com, Chevron, Omnicom Group
U.S. RESEARCH ROUNDUP-Bank Ozk, Bunge, Littelfuse
U.S. RESEARCH ROUNDUP-Humacyte, Hyatt Hotels, Poseida Therapeutics
Intra-Cellular Therapies Inc reports results for the quarter ended in March - Earnings Summary
Brief: Intra-Cellular Therapies Reports First Quarter 2022 Financial Results And Provides Corporate Update
Intra-Cellular Therapies Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Intra-Cellular Therapies Announces FDA Approval Of New Dosage Strengths For Caplyta For Specific Patient Populations
U.S. RESEARCH ROUNDUP-American Airlines, Fulton Financial, Hillman Solutions
U.S. RESEARCH ROUNDUP- Cara Therapeutics, DT Midstream, Fulcrum Therapeutics
U.S. RESEARCH ROUNDUP- Autozone, Domino's Pizza, Salesforce.com
Intra-Cellular Therapies Inc reports results for the quarter ended in December - Earnings Summary
Brief: Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2021 Financial Results And Provides Corporate Update